Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2023-506668-15-00 | Other Identifier | EU CT |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine change in disease symptoms of etentamig compared to standard available therapies in adult participants with relapsed/refractory (R/R) MM.
Etentamig is an investigational drug being developed for the treatment of R/R MM. This study is broken into 2 Arms; Arm A and Arm B. In Arm A, participants will receive etentamig as a monotherapy. In Arm B, participants will receive the standard available therapy (SAT) identified by the Investigator during screening, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable. Around 380 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 140 sites across the world.
In Arm A participants will receive etentamig as an infusion into the vein in 28 day cycles, during the 3.5 year study duration. In Arm B, participants will receive the SAT identified by the Investigator during screening, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable, during the 3.5 year study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Etentamig | Experimental | Participants will receive etentamig as a monotherapy. |
|
| Standard Available Therapy (SAT) | Experimental | Participants will receive SAT, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable. SAT choices are carfilzomib + dexamethasone (Kd), elotuzumab + pomalidomide + dexamethasone (EloPd), selinexor + bortezomib + dexamethasone (SVd). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Etentamig | Drug | Intravenous (IV) Infusion |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Progression Free Survival (PFS) | PFS is defined as the duration from the date of randomization to the date of confirmed disease progression (PD) determined by independent review committee (IRC) per international myeloma working group (IMWG) (2016) response criteria, or death, whichever occurs first. | Up to Approximately 5 Years |
| Objective Response Rate (ORR) | ORR is defined as the percentage of participants who achieve confirmed partial response (PR) + VGPR + complete response (CR) + stringent complete response (sCR) or per IRC assessment. | Up to Approximately 5 Years |
| Measure | Description | Time Frame |
|---|---|---|
| Overall Survival (OS) | OS is defined as the duration from the date of randomization to the date of the participant's death. | Up to Approximately 5 Years |
| Change in Rate of Very Good Partial Response (VGPR) or Better (>= VGPR) |
Not provided
Inclusion Criteria:
Eastern Cooperative Oncology Group (ECOG) performance of <= 2.
Diagnosis of relapsed/refractory (R/R) multiple myeloma (MM) during or after the participant's last treatment as stated in the protocol.
Must have measurable disease with at least 1 of the following assessed within 28 days of enrollment:
Must have received at least 2 or more lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory imide (IMiD), and an anti-CD38 monoclonal antibody (mAb).
-- US and Puerto Rico only: Participant must have received at least 1 or more line of therapy, including exposure to a PI, an IMiD, and an anti-CD38 mAb.
Must be eligible to receive the Investigator's choice standard available therapy (SAT) based on approved prescribing information, previous MM treatment history, and institutional guidelines.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| ABBVIE CALL CENTER | Contact | 844-663-3742 | abbvieclinicaltrials@abbvie.com |
| Name | Affiliation | Role |
|---|---|---|
| ABBVIE INC. | AbbVie | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Alabama at Birmingham - Main /ID# 261434 | Recruiting | Birmingham | Alabama | 35233 | United States | |
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Carfilzomib | Drug | IV Infusion |
|
| Pomalidomide | Drug | Oral Capsule |
|
| Elotuzumab | Drug | IV Infusion |
|
| Selinexor | Drug | Oral Tablet |
|
| Bortezomib | Drug | Subcutaneous or IV Injection |
|
| Dexamethasone | Drug | Oral Tablet or IV Infusion |
|
The rate of >= VGPR is defined as the proportion of participants who achieve a VGPR or better determined by IMWG (2016) response criteria, per IRC assessment, prior to the initiation of new myeloma therapy.
| Up to Approximately 5 Years |
| Change in Rate of CR or Better (>=CR) | >=CR is defined as the percentage of participants who achieve confirmed CR + sCR or per IRC assessment. | Up to Approximately 5 Years |
| Change in Rate of Minimum Residual Disease (MRD) negativity with >= CR | MRD negativity with >= CR, defined as achievement of CR or better by IMWG (2016) response criteria (per IRC assessment) and MRD negative status as assessed by next-generation sequencing (NGS) Adaptive Clonoseq at 10^-5 threshold. | Up to Approximately 5 Years |
| Change from Baseline in Disease Symptoms as Measured by the Disease Symptoms Domain of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Multiple Myeloma Module (EORTC QLQ-MY20) | The disease symptoms domain of EORTC QLQ-MY20 is a 6-item questionnaire to assess the physical function of the participant, with a higher score indicating a higher level of symptoms. | Up to 6 Months |
| Change from Baseline in Physical Functioning as Measured by the Physical Functioning Domain of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) | The physical functioning domain of EORTC QLQ-C30 is a 5-item questionnaire to assess the physical function of the participant, with a higher score indicating worse functioning. | Up to 6 Months |
| Time to Response (TTR) | TTR is defined as the number of months from the date of first dose to the date of best overall response of CR or PR ('responders') determined by IMWG criteria as assessed by IRC. | Up to Approximately 5 Years |
| Duration of Response (DOR) | DOR is defined as the number of days from the day the response criteria are met to the date that disease progression as determined by the IRC. | Up to Approximately 5 Years |
| Time-to-Progression (TTP) | TTP is defined as the number of days from the date of first dose to the date of earliest disease progression as determined by the IRC. | Up to Approximately 5 Years |
| Time to Next Anti-lymphoma Therapy (TTNT) | TTNT is defined as the time from randomization to first documented administration of subsequent anti-lymphoma therapy. | Up to Approximately 5 Years |
| Number of Participants with Event-free Survival (EFS) | EFS is defined as the time from randomization until adverse event determined by the IRC, or death, whichever occurs first. | Up to Approximately 5 Years |
| Change from Baseline in Patient-Reported Outcomes Measurement Information System Fatigue Short Form 7a (PROMIS Fatigue SF 7a) | The PROMIS Fatigue SF7a is a 7-item short form that assesses the impact and experience of fatigue in the past 7 days. For each item, 5-point rating scales are used to measure frequency ("Never," "Rarely," "Sometimes," "Often," or "Always") with a higher score indicating a greater impact. | Up to Approximately 6 Months |
| Change from Baseline in Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE) | The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in participants in cancer clinical trials. PRO-CTCAE items are scored from 0 to 4 to evaluate common symptoms from study treatment on their frequency, severity, interference, amount, presence/absence. | Up to Approximately 6 Months |
| Change from Baseline in Remaining Items in the EORTC QLQ-C30 | The EORTC QLQ-C30 assesses health-related quality of life in cancer patients participating in clinical trials. The EORTC QLQ-C30 comprises 5 functional scales (physical, role, emotional, social, cognitive), 8 single-item symptom scales (fatigue, pain, nausea/vomiting, appetite loss, constipation, diarrhea, insomnia, and dyspnea), as well as subscales assessing global health/quality of life and financial impact. Raw scores are transformed to a scale of 0 to 100, with higher scores representing better functioning/quality of life and greater symptom burden. | Up to Approximately 6 Months |
| Change from Baseline in Remaining Items in the EORTC QLQ-MY20 | The EORTC QLQ-MY20 consists of four scales: two symptom scales (Disease Symptoms [6 items] and Side Effects of Treatment [10 items]), one function scale (Future Perspective [3 items]), and one single item (Body Image). Each item has four response options: "Not at all," "A little," "Quite a bit," or "Very much". All scores are then linearly transformed to a 0 to 100 scale. A higher score on the symptom scales indicates a higher level of symptoms, whereas higher scores on future perspective and body image indicate good functioning or support. | Up to Approximately 6 Months |
| Change from Baseline in European Quality-of-Life 5-dimensional-5-level (EQ-5D-5L) | The EQ-5D-5L is a standardized, non-disease specific instrument used to measure health-related quality of life. The EQ-5D-5L assesses general health on 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/ depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The scores for the 5 dimensions are used to compute a single utility index score ranging from 0 to 1 representing the general health status of the individual, with higher scores indicating better health state. | Up to Approximately 6 Months |
| Change from Baseline in Patient Global Impression of Severity (PGIS) | The self-report measure PGIS reflects a participant's belief about their lymphoma symptoms over the past 7 days. The PGIS is a 5-point scale depicting a participant's rating of overall severity. | Up to Approximately 6 Months |
| Change from Baseline in Patient Global Impression of Change (PGIC) | The self-report measure PGIC reflects a participant's belief about the efficacy of treatment. The PGIC is a 7-point scale depicting a participant's rating of overall improvement since start of treatment. Participants rate their change as very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse. | Up to Approximately 6 Months |
| Number of Participants with Skeletal-Related Event (SRE) | SREs are defined as the presence of any of the following spinal cord compression, pathologic fracture, surgery to bone, or radiation to bone. | Up to Approximately 5 Years |
| Mayo Clinic Hospital - Phoenix /ID# 263326 |
| Recruiting |
| Phoenix |
| Arizona |
| 85054 |
| United States |
| Alta Bates Summit Medical Center for Research /ID# 261438 | Completed | Berkeley | California | 94705 | United States |
| Providence - St. Jude Medical Center /ID# 262031 | Recruiting | Fullerton | California | 92835 | United States |
| VA Loma Linda Healthcare System /ID# 261015 | Recruiting | Loma Linda | California | 92357 | United States |
| Cedars-Sinai Medical Center /ID# 261008 | Recruiting | Los Angeles | California | 90048 | United States |
| Rocky Mountain Cancer Centers - Lone Tree /ID# 278320 | Recruiting | Lone Tree | Colorado | 80124 | United States |
| Mayo Clinic Hospital Jacksonville /ID# 263324 | Recruiting | Jacksonville | Florida | 32224 | United States |
| Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 246230 | Recruiting | Jacksonville | Florida | 32256 | United States |
|
| Winship Cancer Institute of Emory University /ID# 262525 | Recruiting | Atlanta | Georgia | 30322 | United States |
| University of Illinois Hospital and Health Sciences System /ID# 246349 | Recruiting | Chicago | Illinois | 60607 | United States |
| Rush University Medical Center /ID# 265690 | Completed | Chicago | Illinois | 60612 | United States |
| Nancy W. Knowles Cancer Center /ID# 271361 | Recruiting | Elmhurst | Illinois | 60126 | United States |
| Springfield Clinic - First /ID# 262266 | Completed | Springfield | Illinois | 62702 | United States |
| Our Lady Of The Lake Regional Medical Center /ID# 272780 | Recruiting | Baton Rouge | Louisiana | 70808 | United States |
| Center for Cancer and Blood Disorders-American Oncology Partners of Maryland /ID# 263637 | Recruiting | Bethesda | Maryland | 20817 | United States |
| Beth Israel Deaconess Medical Center /ID# 271535 | Recruiting | Boston | Massachusetts | 02215 | United States |
| Dana-Farber Cancer Institute /ID# 261554 | Recruiting | Boston | Massachusetts | 02215 | United States |
| Regents of the University of Michigan /ID# 261577 | Recruiting | Ann Arbor | Michigan | 48109-1276 | United States |
| Karmanos Cancer Institute - Detroit /ID# 266298 | Recruiting | Detroit | Michigan | 48201 | United States |
| Henry Ford Hospital /ID# 262704 | Completed | Detroit | Michigan | 48202 | United States |
| Barbara Ann Karmanos Cancer Institute - McLaren Greater Lansing /ID# 259891 | Recruiting | Lansing | Michigan | 48912 | United States |
| Mayo Clinic - Rochester /ID# 246228 | Recruiting | Rochester | Minnesota | 55905-0001 | United States |
| University of Missouri Hospital /ID# 261553 | Completed | Columbia | Missouri | 65212 | United States |
| Nebraska Cancer Specialists - Omaha - Wright Street /ID# 276772 | Recruiting | Omaha | Nebraska | 68130 | United States |
| New York Cancer & Blood Specialists - Bay Shore /ID# 261524 | Recruiting | Bay Shore | New York | 11706 | United States |
| New York Cancer & Blood Specialists - Lake Success Medical Oncology /ID# 262953 | Completed | New Hyde Park | New York | 11042 | United States |
| New York Cancer and Blood Specialists - New York /ID# 262951 | Completed | New York | New York | 10028 | United States |
| Eastchester Center for Cancer Care /ID# 262952 | Recruiting | The Bronx | New York | 10469 | United States |
| University of North Carolina /ID# 259854 | Recruiting | Chapel Hill | North Carolina | 27514 | United States |
| Atrium Health Levine Cancer Institute /ID# 246199 | Recruiting | Charlotte | North Carolina | 28204 | United States |
| Duke University Medical Center /ID# 259694 | Completed | Durham | North Carolina | 27710 | United States |
| University Of Cincinnati Medical Center /ID# 246415 | Completed | Cincinnati | Ohio | 45219 | United States |
| Cleveland Clinic Main Campus /ID# 246183 | Recruiting | Cleveland | Ohio | 44195 | United States |
| Oregon Medical Research Center /ID# 262335 | Recruiting | Portland | Oregon | 97239 | United States |
| Medical University of South Carolina /ID# 259692 | Recruiting | Charleston | South Carolina | 29425 | United States |
| University of Tennessee Health Science Center /ID# 261622 | Recruiting | Memphis | Tennessee | 38103 | United States |
| Baptist Memorial Hospital /ID# 270910 | Recruiting | Memphis | Tennessee | 38120 | United States |
| The West Clinic /ID# 262444 | Recruiting | Memphis | Tennessee | 38120 | United States |
|
| Vanderbilt University Medical Center /ID# 261621 | Recruiting | Nashville | Tennessee | 37232-0011 | United States |
| Oncology Consultants /ID# 276774 | Recruiting | Houston | Texas | 77030 | United States |
| Texas Oncology - Northeast Texas /ID# 278304 | Recruiting | Tyler | Texas | 75702 | United States |
| Virginia Cancer Specialists - Fairfax /ID# 262792 | Recruiting | Fairfax | Virginia | 22031 | United States |
| Virginia Oncology Associates - Norfolk (Lake Wright) /ID# 278314 | Completed | Norfolk | Virginia | 23502 | United States |
| VCU Massey Cancer Center: Dalton Oncology Clinic /ID# 261944 | Recruiting | Richmond | Virginia | 23298 | United States |
| Northwest Medical Specialties Tacoma /ID# 276281 | Recruiting | Tacoma | Washington | 98405 | United States |
| St George Hospital - Kogarah /ID# 261806 | Recruiting | Kogarah | New South Wales | 2217 | Australia |
| Liverpool Hospital /ID# 262159 | Recruiting | Liverpool | New South Wales | 2170 | Australia |
| Calvary Mater Newcastle /ID# 261804 | Recruiting | Waratah | New South Wales | 2298 | Australia |
| Princess Alexandra Hospital - Woolloongabba /ID# 261810 | Recruiting | Woolloongabba | Queensland | 4102 | Australia |
| Monash Health - Monash Medical Centre - Clayton /ID# 262158 | Recruiting | Clayton | Victoria | 3168 | Australia |
| St Vincent's Hospital Melbourne /ID# 261808 | Recruiting | Fitzroy Melbourne | Victoria | 3065 | Australia |
| Box Hill Hospital /ID# 262784 | Recruiting | Melbourne | Victoria | 3128 | Australia |
| Universitaetsklinikum Krems /ID# 261509 | Recruiting | Krems | Lower Austria | 3500 | Austria |
| Klinik Ottakring /ID# 245829 | Recruiting | Vienna | State of Vienna | 1160 | Austria |
| Medizinische Universitaet Graz /ID# 261908 | Recruiting | Graz | Styria | 8010 | Austria |
| Ordensklinikum Linz Elisabethinen /ID# 245609 | Recruiting | Linz | Upper Austria | 4010 | Austria |
| Algemeen Ziekenhuis klina /ID# 260856 | Recruiting | Brasschaat | Antwerpen | 2930 | Belgium |
| Algemeen Ziekenhuis Sint-Jan Brugge /ID# 245345 | Completed | Bruges | West-Vlaanderen | 8000 | Belgium |
| University Health Network_Princess Margaret Cancer Centre /ID# 261566 | Completed | Toronto | Ontario | M5G 2M9 | Canada |
| Beijing Chaoyang Hospital,Capital Medical University /ID# 245533 | Recruiting | Beijing | Beijing Municipality | 100020 | China |
| Peking Union Medical College Hospital East - Dongdan Campus /ID# 245545 | Recruiting | Beijing | Beijing Municipality | 100730 | China |
| Fujian Medical University Union Hospital /ID# 245558 | Recruiting | Fuzhou | Fujian | 350001 | China |
| Sun Yat-Sen University Cancer Center /ID# 245542 | Recruiting | Guangzhou | Guangdong | 510060 | China |
| People's Hospital of Henan Province /ID# 260918 | Recruiting | Zhengzhou | Henan | 450003 | China |
| Henan Cancer Hospital /ID# 245536 | Recruiting | Zhengzhou | Henan | 450008 | China |
| Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 245549 | Recruiting | Wuhan | Hubei | 430022 | China |
| Zhongda Hospital Southeast University /ID# 245563 | Recruiting | Nanjing | Jiangsu | 210009 | China |
| The First Affiliated Hospital of Soochow University /ID# 245544 | Recruiting | Suzhou | Jiangsu | 215006 | China |
| The First Affiliated Hospital of Nanchang University /ID# 245537 | Recruiting | Nanchang | Jiangxi | 330006 | China |
| First Affiliated Hospital of China Medical University /ID# 245547 | Recruiting | Shenyang | Liaoning | 110001 | China |
| Second Affiliated Hospital of Xian Jiaotong University /ID# 261255 | Recruiting | Xi'an | Shaanxi | 710004 | China |
| Shanghai Tongji Hospital /ID# 245539 | Recruiting | Shanghai | Shanghai Municipality | 200065 | China |
| Institute of Hematology and Blood Diseases Hospital /ID# 265702 | Recruiting | Tianjin | Tianjin Municipality | 300020 | China |
| Tianjin Medical University General Hospital /ID# 260851 | Recruiting | Tianjin | Tianjin Municipality | 300052 | China |
| The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 260883 | Recruiting | Hangzhou | Zhejiang | 310003 | China |
| Sir Run Run Shaw Hospital Zhejiang University School of Medicine /ID# 260882 | Recruiting | Hangzhou | Zhejiang | 310020 | China |
| The First Affiliated Hospital of Wenzhou Medical University /ID# 245550 | Recruiting | Wenzhou | Zhejiang | 325000 | China |
| Fakultni Nemocnice Brno - Jihlavska /ID# 245689 | Completed | Brno | Brno-mesto | 625 00 | Czechia |
| Fakultni Nemocnice Ostrava /ID# 245686 | Recruiting | Ostrava | Ostrava-mesto | 708 52 | Czechia |
| Vseobecna Fakultni nemocnice v Praze /ID# 245691 | Recruiting | Prague | Praha 17 | 128 00 | Czechia |
| Fakultni nemocnice Hradec Kralove - Sokolska /ID# 245690 | Recruiting | Hradec Králové | 500 05 | Czechia |
| Odense University Hospital /ID# 260924 | Recruiting | Odense | Region Syddanmark | 5000 | Denmark |
| Vejle Sygehus /ID# 260923 | Recruiting | Vejle | Region Syddanmark | 7100 | Denmark |
| CH Saint-Quentin /ID# 261856 | Completed | Saint-Quentin | Aisne | 02321 | France |
| Centre Hospitalier du Mans /ID# 261852 | Recruiting | Le Mans | Sarthe | 72037 | France |
| CH Henri Duffaut /ID# 261844 | Recruiting | Avignon | Vaucluse | 84902 | France |
| Centre Hospitalier Régional d'Orléans - Hôpital de la Source /ID# 261854 | Completed | Orléans | 45067 | France |
| Universitaetsklinikum Freiburg /ID# 262147 | Recruiting | Freiburg im Breisgau | Baden-Wurttemberg | 79106 | Germany |
| Staedtisches Klinikum Karlsruhe /ID# 272377 | Recruiting | Karlsruhe | Baden-Wurttemberg | 76133 | Germany |
| Klinikum Chemnitz - Flemmingstraße /ID# 273108 | Completed | Chemnitz | Saxony | 09116 | Germany |
| Charite Universitaetsklinikum Berlin - Campus Benjamin Franklin /ID# 260689 | Recruiting | Berlin | 12203 | Germany |
| Centrum fuer Haematologie und Onkologie Bethanien /ID# 271982 | Recruiting | Frankfurt am Main | 60389 | Germany |
| Universitaetsklinikum Hamburg-Eppendorf /ID# 260651 | Completed | Hamburg | 20246 | Germany |
| Alexandra General Hospital /ID# 240591 | Recruiting | Athens | Attica | 11528 | Greece |
| University General Hospital Attikon /ID# 240592 | Recruiting | Chaïdári | Attica | 12462 | Greece |
| General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 240596 | Recruiting | Athens | 10676 | Greece |
| General University Hospital of Thessaloniki AXEPA /ID# 240595 | Recruiting | Thessaloniki | 54636 | Greece |
| Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz /ID# 261648 | Recruiting | Győr | Győr-Moson-Sopron | 9024 | Hungary |
| Semmelweis Egyetem /ID# 261646 | Recruiting | Budapest | 1085 | Hungary |
| Semmelweis Egyetem /ID# 261647 | Recruiting | Budapest | 1085 | Hungary |
| Rabin Medical Center. /ID# 245498 | Recruiting | Petah Tikva | Central District | 4941492 | Israel |
| Shaare Zedek Medical Center /ID# 245681 | Recruiting | Jerusalem | Jerusalem | 91031 | Israel |
| The Chaim Sheba Medical Center /ID# 245497 | Recruiting | Ramat Gan | Tel Aviv | 5265601 | Israel |
| Tel Aviv Sourasky Medical Center /ID# 245495 | Recruiting | Tel Aviv | Tel Aviv | 6423906 | Israel |
| ASST Ovest Milanese /ID# 256813 | Recruiting | Legnano | Milano | 20025 | Italy |
| A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 256808 | Recruiting | Turin | Piedmont | 10126 | Italy |
| Azienda Ospedaliero-Universitaria Policlinico Umberto I /ID# 256810 | Recruiting | Rome | Roma | 00161 | Italy |
| Azienda Ospedaliero Universitaria delle Marche /ID# 256812 | Recruiting | Ancona | 60126 | Italy |
| AOU Policlinico G. Rodolico - San Marco /ID# 256814 | Recruiting | Catania | 95123 | Italy |
| Anjo Kosei Hospital /ID# 263434 | Recruiting | Anjo | Aichi-ken | 446-8602 | Japan |
| Nagoya City University Hospital /ID# 263320 | Recruiting | Nagoya | Aichi-ken | 467-8602 | Japan |
| Chiba University Hospital /ID# 262006 | Completed | Chiba | Chiba | 260-8677 | Japan |
| University of Fukui Hospital /ID# 264222 | Recruiting | Yoshida-gun | Fukui | 910-1104 | Japan |
| Kyushu University Hospital /ID# 264704 | Completed | Fukuoka | Fukuoka | 812-8582 | Japan |
| Gifu Municipal Hospital /ID# 263321 | Recruiting | Gifu | Gifu | 500-8323 | Japan |
| Gunma University Hospital /ID# 262580 | Completed | Maebashi | Gunma | 371-8511 | Japan |
| Chugoku Central Hospital /ID# 263431 | Recruiting | Fukuyama | Hiroshima | 720-0001 | Japan |
| Hyogo Prefectural Amagasaki General Medical Center /ID# 265696 | Recruiting | Amagasaki | Hyōgo | 660-8550 | Japan |
| University Hospital Kyoto Prefectural University of Medicine /ID# 262585 | Recruiting | Kyoto | Kyoto | 602-8566 | Japan |
| Miyagi Cancer Center /ID# 265094 | Recruiting | Natori-shi | Miyagi | 981-1293 | Japan |
| Naha City Hospital /ID# 263972 | Recruiting | Naha | Okinawa | 902-0061 | Japan |
| The University of Osaka Hospital /ID# 263974 | Recruiting | Suita-shi | Osaka | 565-0871 | Japan |
| Saitama Prefectural Cancer Center /ID# 262586 | Recruiting | Kitaadachi-gun | Saitama | 362-0806 | Japan |
| Tokyo Metropolitan Komagome Hospital /ID# 277567 | Recruiting | Bunkyo Ku | Tokyo | 113-8677 | Japan |
| Japanese Red Cross Medical Center /ID# 261717 | Recruiting | Shibuya-ku | Tokyo | 150-8935 | Japan |
| University of Yamanashi Hospital /ID# 262912 | Completed | Chuo-shi | Yamanashi | 409-3898 | Japan |
| Uniwersytecki Szpital Kliniczny We Wroclawiu /ID# 260172 | Active, not recruiting | Wroclaw | Lower Silesian Voivodeship | 50-556 | Poland |
| Uniwersytecki Szpital Kliniczny Nr 1 w Lublinie /ID# 260168 | Active, not recruiting | Lublin | Lublin Voivodeship | 20-081 | Poland |
| Uniwersyteckie Centrum Kliniczne /ID# 260169 | Active, not recruiting | Gdansk | Pomeranian Voivodeship | 80-214 | Poland |
| Fundacao Champalimaud /ID# 246258 | Recruiting | Lisbon | Lisbon District | 1400-038 | Portugal |
| Unidade Local de Saude de Santa Maria /ID# 246255 | Recruiting | Lisbon | 1649-035 | Portugal |
| Instituto Portugues de Oncologia do Porto Francisco Gentil /ID# 246257 | Recruiting | Porto | 4200-072 | Portugal |
| Hematology And Oncology Institute /ID# 272531 | Completed | Manati | 00674 | Puerto Rico |
| Auxilio Mutuo Cancer Center /ID# 272565 | Completed | San Juan | 00918 | Puerto Rico |
| Alberts Cellular Therapy /ID# 245725 | Recruiting | Pretoria | Gauteng | 0044 | South Africa |
| Constantiaberg Haematology /ID# 261320 | Recruiting | Cape Town | Western Cape | 7800 | South Africa |
| Haemalife Inc. /ID# 245724 | Recruiting | Kuils River | Western Cape | 7580 | South Africa |
| Seoul National University Hospital /ID# 245491 | Recruiting | Seoul | Seoul Teugbyeolsi | 03080 | South Korea |
| Samsung Medical Center /ID# 245492 | Recruiting | Seoul | Seoul Teugbyeolsi | 06351 | South Korea |
| The Catholic University of Korea, Seoul St. Marys Hospital /ID# 245493 | Recruiting | Seoul | Seoul Teugbyeolsi | 06591 | South Korea |
| Ulsan University Hospital /ID# 245490 | Recruiting | Ulsan | Ulsan Gwang Yeogsi | 44033 | South Korea |
| Yonsei University Health System Severance Hospital /ID# 245489 | Completed | Seoul | 03722 | South Korea |
| Instituto Catalan de Oncologia (ICO) Badalona /ID# 246398 | Recruiting | Badalona | Barcelona | 08916 | Spain |
| Complejo Hospitalario Universitario Ourense /ID# 246400 | Recruiting | Ourense | Ourense | 32005 | Spain |
| Hospital de Leon /ID# 261624 | Recruiting | León | 24071 | Spain |
| Hospital General Universitario Gregorio Maranon /ID# 246401 | Recruiting | Madrid | 28007 | Spain |
| Hospital Universitario de Salamanca /ID# 262218 | Recruiting | Salamanca | 37711 | Spain |
| Hospital Universitario y Politecnico La Fe /ID# 261625 | Recruiting | Valencia | 46026 | Spain |
| Helsingborgs Lasarett /ID# 262513 | Completed | Helsingborg | Skåne County | 251 87 | Sweden |
| Uddevalla sjukhus /ID# 262034 | Recruiting | Uddevalla | Västra Götaland County | 451 80 | Sweden |
| Falu Lasarett /ID# 262231 | Recruiting | Falun | 791 82 | Sweden |
| China Medical University Hospital /ID# 245483 | Recruiting | Taichung | 40447 | Taiwan |
| Taichung Veterans General Hospital /ID# 261142 | Recruiting | Taichung | 40705 | Taiwan |
| National Taiwan University Hospital /ID# 245482 | Recruiting | Taipei | 100 | Taiwan |
| Istanbul Florence Nightingale Hospital /ID# 271543 | Recruiting | Şişli | Istanbul | 34381 | Turkey (Türkiye) |
| Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi /ID# 261672 | Recruiting | Ankara | 06200 | Turkey (Türkiye) |
| Antalya Egitim Ve Arastirma Hastanesi /ID# 261674 | Recruiting | Antalya | 07100 | Turkey (Türkiye) |
| Trakya University Medical Facu /ID# 261673 | Recruiting | Edirne, Istanbul | 22030 | Turkey (Türkiye) |
| Addenbrookes Hospital /ID# 261104 | Recruiting | Cambridge | Cambridgeshire | CB2 2QQ | United Kingdom |
| Western General Hospital - NHS Lothian /ID# 261106 | Recruiting | Edinburgh | Edinburgh, City of | EH4 2XU | United Kingdom |
| Dup_Guys and St Thomas NHS Foundation Trust - Guy's Hospital /ID# 262488 | Recruiting | London | Greater London | SE1 9RT | United Kingdom |
| Nottingham City Hospital /ID# 261105 | Recruiting | Nottingham | Nottinghamshire | NG5 1PB | United Kingdom |
| Leeds Teaching Hospitals NHS Trust /ID# 261101 | Recruiting | Leeds | West Yorkshire | LS9 7TF | United Kingdom |
|
| The Royal Marsden NHS Foundation Trust /ID# 262470 | Recruiting | London | SW3 6JJ | United Kingdom |
| The Christie Hospital /ID# 261102 | Recruiting | Manchester | M20 4BX | United Kingdom |
| ID | Term |
|---|---|
| D009101 | Multiple Myeloma |
| ID | Term |
|---|---|
| D054219 | Neoplasms, Plasma Cell |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D020141 | Hemostatic Disorders |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D010265 | Paraproteinemias |
| D001796 | Blood Protein Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006474 | Hemorrhagic Disorders |
| D008232 | Lymphoproliferative Disorders |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C524865 | carfilzomib |
| C467566 | pomalidomide |
| C546027 | elotuzumab |
| C585161 | selinexor |
| D000069286 | Bortezomib |
| D003907 | Dexamethasone |
| ID | Term |
|---|---|
| D001897 | Boronic Acids |
| D000148 | Acids, Noncarboxylic |
| D000143 | Acids |
| D007287 | Inorganic Chemicals |
| D001896 | Boron Compounds |
| D009930 | Organic Chemicals |
| D011719 | Pyrazines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D011246 | Pregnadienetriols |
| D011245 | Pregnadienes |
| D011278 | Pregnanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D013259 | Steroids, Fluorinated |
Not provided
Not provided